As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cytokinetics, Incorporated. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 14.5%. 10 filings are on record since August 7, 2025 (Schedule 13G/A, February 17, 2026).
Sell to companies like Cytokinetics, Incorporated? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 6,231,890 · Sole dispositive: 0 · Shared dispositive: 7,116,724 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Fmr LLC · Sole voting: 5,220,899 · Shared voting: 0 · Sole dispositive: 5,248,580 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-08
- · Holder: Fmr LLC · Percent: 9% · SCHEDULE 13G/A
- · Reporting person: Vanguard Capital Management · Sole voting: 933,408 · Shared voting: 0 · Sole dispositive: 6,422,042 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Cytokinetics, Incorporated has 10 Schedule 13D or 13G filings on record since 2025-08-07. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.5% | 17,716,372 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Vanguard Capital Management | 5.21% | 6,422,042 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Wellington Management Group LLP | 5.1% | 7,116,724 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| State Street Corporation | 4.7% | 5,617,334 | SCHEDULE 13G, 2025-11-10 | 2025-09-30 |
| Fmr LLC | 3.9% | 5,248,580 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Cytokinetics, Incorporated and the warning signs.
Free to see. No signup.
Keep reading
More on Cytokinetics, Incorporated and the records around it.
Cytokinetics, Incorporated elsewhere on the record
Companies that share a holder
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch Cytokinetics, Incorporated
Get an email when Cytokinetics, Incorporated files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cytokinetics, Incorporated?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cytokinetics, Incorporated: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cytokinetics, Incorporated covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 933,408 | 0 | 6,422,042 | 0 | SCHEDULE 13G, 2026-04-29 |
| Wellington Management Group LLP | 0 | 6,231,890 | 0 | 7,116,724 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Group Holdings LLP | 0 | 6,231,890 | 0 | 7,116,724 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Investment Advisors Holdings LLP | 0 | 6,231,890 | 0 | 7,116,724 | SCHEDULE 13G/A, 2026-08-13 |
| Fmr LLC | 5,220,899 | 0 | 5,248,580 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Abigail P. Johnson | 0 | 0 | 5,248,580 | 0 | SCHEDULE 13G/A, 2026-07-08 |
The latest filing identifies Cytokinetics, Incorporated by CUSIP 23282W605 and gives its principal executive office as 350 Oyster Point Blvd, South San Francisco (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Fmr LLC | 10.9% | SCHEDULE 13G/A |
| 2025-08-14 | T. Rowe Price Investment Management, Inc. | 14.7% | SCHEDULE 13G/A |
| 2025-11-10 | State Street Corporation | 4.7% | SCHEDULE 13G |
| 2025-11-14 | T. Rowe Price Investment Management, Inc. | 16% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 14.5% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.21% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 9% | SCHEDULE 13G/A |
| 2026-07-08 | Fmr LLC | 3.9% | SCHEDULE 13G/A |
| 2026-08-13 | Wellington Management Group LLP | 5.1% | SCHEDULE 13G/A |
Questions about who owns Cytokinetics, Incorporated
Who owns Cytokinetics, Incorporated?
On this page, 3 holders' latest ownership filings report 5% or more of Cytokinetics, Incorporated: T. Rowe Price Investment Management, Inc. (14.5%, Schedule 13G/A, filed 2026-02-17), Vanguard Capital Management (5.21%, Schedule 13G, filed 2026-04-29) and Wellington Management Group LLP (5.1%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Cytokinetics, Incorporated?
By the share each holder's latest filing reports, the largest holders of Cytokinetics, Incorporated on this page are T. Rowe Price Investment Management, Inc. (14.5%), Vanguard Capital Management (5.21%) and Wellington Management Group LLP (5.1%).
When did T. Rowe Price Investment Management, Inc. buy into Cytokinetics, Incorporated?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 14.7%; its latest, Schedule 13G/A filed 2026-02-17, reports 14.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Cytokinetics, Incorporated. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.